80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]李萍,莊捷,孫紅,等.間變性淋巴瘤激酶抑制劑的遴選量化評估[J].福建醫(yī)藥雜志,2025,47(01):1-5.[doi:10.20148/j.fmj.2025.01.001]
　LI Ping,ZHUANG Jie,SUN Hong,et al.Selection and quantitative evaluation of anaplastic lymphoma kinase inhibitors[J].FUJIAN MEDICAL JOURNAL,2025,47(01):1-5.[doi:10.20148/j.fmj.2025.01.001]
點(diǎn)擊復(fù)制

間變性淋巴瘤激酶抑制劑的遴選量化評估()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
47
期數(shù):
2025年01期
頁碼:
1-5
欄目:
臨床研究
出版日期:
2025-01-20

文章信息/Info

Title:
Selection and quantitative evaluation of anaplastic lymphoma kinase inhibitors
文章編號:
1002-2600(2025)01-0001-05
作者:
李萍; 莊捷; 孫紅; 馮彩萍; 魏曉霞; 蔡加琴
福州大學(xué)附屬省立醫(yī)院藥學(xué)部,福州 350001
Author(s):
LI Ping;  ZHUANG Jie;  SUN Hong;  FENG Caiping;  WEI Xiaoxia;  CAI Jiaqin
Department of Pharmacy, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian 350001, China
關(guān)鍵詞:
克唑替尼;  塞瑞替尼;  阿來替尼;  布格替尼;  恩沙替尼;  洛拉替尼;  藥品遴選
Keywords:
crizotinib;  ceritinib;  alectinib;  brigatinib;  ensartinib;  lorlatinib;  drug selection
分類號:
R979.1
DOI:
10.20148/j.fmj.2025.01.001
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 通過對克唑替尼、塞瑞替尼、阿來替尼、布格替尼、恩沙替尼和洛拉替尼進(jìn)行量化評估,為醫(yī)療機(jī)構(gòu)遴選間變性淋巴瘤激酶抑制劑(ALK-TKIs)提供依據(jù)。方法 應(yīng)用《中國醫(yī)療機(jī)構(gòu)藥品評價(jià)與遴選快速指南》的評價(jià)維度、評價(jià)細(xì)則及評價(jià)方法,對克唑替尼、塞瑞替尼、阿來替尼、布格替尼、恩沙替尼和洛拉替尼進(jìn)行藥品評價(jià)。結(jié)果 克唑替尼、塞瑞替尼、阿來替尼、布格替尼、恩沙替尼和洛拉替尼的遴選量化評估總分分別為79.12、80.50、79.99、82.00、70.14、79.31分。結(jié)論 根據(jù)評分結(jié)果,醫(yī)療機(jī)構(gòu)在引入ALK-TKIs時(shí),建議遴選的順序依次為布格替尼、塞瑞替尼、阿來替尼、洛拉替尼、克唑替尼、恩沙替尼。
Abstract:
Objective To perform quantitative evaluation for crizotinib, ceritinib, alectinib, brigatinib, ensartinib and lorlatinib, so as to provide a basis for selecting anaplastic lymphoma kinase inhibitors(ALK-TKIs)for medical institutions. Methods The drug evaluation of crizotinib, ceritinib, alectinib, brigatinib, ensartinib and lorlatinib was carried out by using the evaluation dimensions, evaluation rules and evaluation methods of the " Quick Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions". Results The overall score of crizotinib, ceritinib, alectinib, brigatinib, ensartinib and loratinib was 79.12, 80.50, 79.99, 82.00, 70.14, 79.31. Conclusion According to the score results, when introducing ALK-TKIs in medical institutions, the recommended selection order is brigatinib, ceritinib, alectinib, lorlatinib, crizotinib,and ensartinib.

參考文獻(xiàn)/References:

[1] Duma N, Santana-Davila R, Molina J R. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment[J]. Mayo Clin Proc, 2019, 94(8): 1623-1640.
[2] 趙志剛, 董占軍, 劉建平. 中國醫(yī)療機(jī)構(gòu)藥品評價(jià)與遴選快速指南(第二版)[J]. 醫(yī)藥導(dǎo)報(bào), 2023, 42(4): 447-456.
[3] 徐子鈞, 胡繼繁, 劉子玲. ALK陽性非小細(xì)胞肺癌靶向治療耐藥機(jī)制及治療管理的研究進(jìn)展[J]. 中國腫瘤臨床, 2022, 49(5): 254-258.
[4] Zhao D, Chen J, Chu M, et al. Pharmacokinetic-based drug-drug interactions with anaplastic lymphoma kinase inhibitors: a review[J]. Drug Des Devel Ther, 2020, 14: 1663-1681.
[5] Gupta N, Wang X, Offman E, et al. Population pharmacokinetics of brigatinib in healthy volunteers and patients with cancer[J]. Clin Pharmacokinet, 2021, 60(2): 235-247.
[6] Horn L, Infante J R, Reckamp K L, et al. Ensartinib(X-396)in ALK-positive non-small cell lung cancer: results from a first-in-human phase Ⅰ/Ⅱ, multicenter study[J]. Clin Cancer Res, 2018, 24(12): 2771-2779.
[7] Ma Y, Pan H, Liu Y, et al. Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial[J]. J Thorac Dis, 2022, 14(12): 4751-4762.
[8] Chen J, OGorman M T, James L P, et al. Pharmacokinetics of lorlatinib after single and multiple dosing in patients with anaplastic lymphoma kinase(ALK)-positive non-small cell lung cancer: results from a global phase Ⅰ/Ⅱ Study[J]. Clin Pharmacokinet, 2021, 60(10): 1313-1324.
[9] Riely G J, Wood D E, Ettinger D S,et al.Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology[J]. Journal of the National Comprehensive Cancer Network, 2024,22(4): 249-274.
[10] 中國臨床腫瘤學(xué)會指南工作委員會. CSCO非小細(xì)胞肺癌診療指南2024[M]. 北京: 人民衛(wèi)生出版社, 2024: 95-99.
[11] Solomon B J, Mok T, Kim D W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. N Engl J Med, 2014, 371(23): 2167-2177.
[12] Soria J C, Tan D S W, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer(ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet, 2017, 389(10072): 917-929.
[13] Mok T, Camidge D R, Gadgeel S M, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Ann Oncol, 2020, 31(8): 1056-1064.
[14] Camidge D R, Kim H R, Ahn M J, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: Final results of phase 3 ALTA-1L trial[J]. J Thorac Oncol, 2021, 16(12): 2091-2108.
[15] Horn L, Wang Z, Wu G, et al. Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial[J]. JAMA Oncol, 2021, 7(11): 1617-1625.
[16] Solomon B J, Bauer T M, Mok T S K, et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study[J]. Lancet Respir Med, 2023, 11(4): 354-366.
[17] Jiang J, Zhao C, Zhang F, et al. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis[J]. BMJ Open, 2022, 12(9): e060782.
[18] Tao Y, Zhou Y, Tang L, et al. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: a systematic review and meta-analysis[J]. Invest New Drugs, 2022, 40(4): 831-840.
[19] Gupta N, Hanley M J, Kerstein D, et al. Effect of severe renal impairment on the pharmacokinetics of brigatinib[J]. Invest New Drugs, 2021, 39(5): 1306-1314.
[20] Hanley M J, Kerstein D, Tugnait M, et al. Brigatinib pharmacokinetics in patients with chronic hepatic impairment[J]. Invest New Drugs, 2023, 41(3): 402-410.
[21] Morcos P N, Cleary Y, Sturm-Pellanda C, et al. Effect of hepatic impairment on the pharmacokinetics of alectinib[J]. J Clin Pharmacol, 2018, 58(12): 1618-1628.
[22] Lin S, Gong J, Canas G C, et al. A phase I study to evaluate the pharmacokinetics and safety of lorlatinib in adults with mild, moderate, and severe renal impairment[J]. Eur J Drug Metab Pharmacokinet, 2022, 47(2): 235-245.
[23] Team R. Lorlatinib(Lorbrena)[J]. Can J Health Technol, 2022, 2(4): 1-21.
[24] Zhao D, Chen J, Long X, et al. Dose adjustment for tyrosine kinase inhibitors in nonsmall cell lung cancer patients with hepatic or renal function impairment(Review)[J]. Oncol Rep, 2021, 45(2): 413-426.
[25] Tugnait M, Gupta N, Hanley M J, et al. Effects of strong CYP2C8 or CYP3A inhibition and CYP3A induction on the pharmacokinetics of brigatinib, an oral anaplastic lymphoma kinase inhibitor, in healthy volunteers[J]. Clin Pharmacol Drug Dev, 2020, 9(2): 214-223.
[26] Patel M, Chen J, McGrory S, et al. The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants[J]. Invest New Drugs, 2020, 38(1): 131-139.
[27] Chen J, Xu H, Pawlak S, et al. The effect of rifampin on the pharmacokinetics and safety of lorlatinib: results of a phase one, open-label, crossover study in healthy participants[J]. Adv Ther, 2020, 37(2): 745-758.
[28] Morcos P N, Cleary Y, Guerini E, et al. Clinical drug-drug interactions through cytochrome P450 3A(CYP3A)for the selective ALK inhibitor alectinib[J]. Clin Pharmacol Drug Dev, 2017, 6(3): 280-291.
[29] 申越, 王睿, 高婧, 等. 非小細(xì)胞肺癌小分子的靶向治療研究進(jìn)展[J].世界腫瘤研究, 2022, 12(2): 90-98.
[30] 許佳藝,代展菁,盧鈺瓊,等.ALK-TKIs治療ALK陽性非小細(xì)胞肺癌藥物經(jīng)濟(jì)學(xué)的系統(tǒng)評價(jià)[J].中國循證醫(yī)學(xué)雜志,2022,22(12):1428-1435.

更新日期/Last Update: 2025-01-20